Drug intelligence / Profile preview

Quella

Development stage: Unknown
Lead developer: MTI Medical
Modality: Small Molecules
Administration: Oral

Overview

Quella is an oral dietary supplement developed and marketed by MTI Medical. It is formulated as a tablet containing a combination of 100 mg of Ubidecarenone (Coenzyme Q10) and 12.31 mg of Tocopheryl (Vitamin E). The product is indicated for antioxidant support and the promotion of cardiovascular health. Ubidecarenone serves as a vital electron carrier in the mitochondrial respiratory chain, supporting cellular energy production, while both ingredients function as potent antioxidants to protect cells and tissues from oxidative damage.

Brand names: Quella
Other names: Quella TabletsCoQ10 and vitamin E combinationCoQ-10 and vitamin E combinationCoQ 10 and vitamin E combination

Targets

ND1 (Mitochondrial electron transport chain complex I)

Beyond the preview

Go deeper on Quella.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quella.

Explore the full profile